Submission of Written Information

To fulfill its change describe above, the Working Group has been conducting a public dialogue on health care in America through public meetings held across the country and through comments received on its Web site, http://www.citizenshealthcare.gov. The Working Group invites members of the public to the Web site to be part of that dialogue.

Further, the Working Group will accept written submissions for consideration at the Working Group business meeting listed above. In general, individuals or organizations wishing to provide written information for consideration by the Citizens’ Health Care Working Group at this meeting should submit information electronically to citizenshealth@ahraq.gov.

This notice is published less than 15 days in advance of the meeting due to logistical difficulties.

Carolyn M. Clancy,
Director.

[FR Doc. 06–4573 Filed 5–11–06; 1:38 pm] BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:


Times And Dates:
7 p.m.–9 p.m., June 5, 2006 (Closed).
8 a.m.–5 p.m., June 6, 2006 (Closed).
8 a.m.–5 p.m., June 7, 2006 (Closed).

Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue, NW, Washington, DC 20036, telephone (202) 776–9279.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552(b)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to Be Discussed: The meeting will include the review, discussion, and evaluation of research grants in response to NIOSH RFA OH–06–002, Prevention of Airborne Infections in Occupational Settings.

For More Information Contact:
Bernadine B. Kuchinski, Scientific Review Administrator, Robert A. Taft Laboratory, 4676 Columbia Parkway, MS C–7, Cincinnati, OH 45226, phone (513) 533–8511, e-mail bbk1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E6–7319 Filed 5–12–06; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Health Promotion and Disease Prevention Grant Program: Correction

ACTION: Notice; correction.

SUMMARY: The Indian Health Service published a document in the Federal Register on April 5, 2006. The document contained one error.

FOR FURTHER INFORMATION CONTACT:
Alberta Becenti, Health Promotion and Disease Prevention Consultant, Indian Health Service, Reyes Building, 801 Thompson Avenue, Suite 307, Rockville, MD 20852, Telephone (301) 443–4305. (This is not a toll-free number.)

Correction

In the Federal Register of April 5, 2006, in FR Doc. 06–3257, on page 17111, in the second column, correct by deleting Section VIII. Other Information in its entirety.

Dated: May 9, 2006.
Robert G. McSwain,
Deputy Director, Indian Health Service.

[FR Doc. 06–4506 Filed 5–12–06; 8:45 am] BILLING CODE 4165–16–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Availability of Draft Guideline; Comment Request

AGENCY: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services.


SUMMARY: The Center for Substance Abuse Treatment is seeking public comments on the revised draft Guidelines for the Accreditation of Opioid Treatment Programs. These guidelines elaborate upon the Federal opioid treatment standards set forth under 42 CFR part 8.

DATES: Comments should be submitted by July 14, 2006.

ADDRESSES: The draft guideline may be obtained directly from http:// www.dpt.samhsa.gov, or by contacting the Division of Pharmacologic Therapy with the information provided below. Comments should be submitted to the Division of Pharmacologic Therapy, Center for Substance Abuse Treatment, 1 Choke Cherry Road, Room 2–1080, Rockville, MD, 20857; Attention: DPT Federal Register Representative. Comments may also be faxed to 240–276–2710 or e-mailed to OTP–Guidelines@samhsa.hhs.gov. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Sarah Crowley, Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapy, 1 Choke Cherry Road, Room 2–1080, Rockville, MD 20857, (240–276–2704, e-mail: Sarah.Crowley@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Background

Federal Regulations codified under 42 CFR part 8 set forth requirements for opioid treatment programs (“OTPs”), also known as methadone treatment programs. The regulations, which were the subject of a Final Rule published in the Federal Register on January 17, 2001, (“Final Rule” 66 FR 4075–4102, January 17, 2001) include standards for opioid treatment. OTPs are required to provide treatment in accordance with these standards as a basis for CSAT certification. These standards address patient admission requirements,